Visit Booth #1301

We are looking forward to seeing you at the 2019 AACC annual meeting in Anaheim, California. Grifols advances patient care with innovative diagnostic solutions that improve the detection and management of disease and simplify laboratory operations. Please take a moment to stop by the Grifols booth where you can learn more about the different solutions that we offer to help clinical diagnostic professionals.
 
The exhibition hours are as follows:  
 
Tuesday, August 6 9:30 am – 5:00 pm
Wednesday, August 7 9:30 am – 5:00 pm
Thursday, August 8 9:30 am – 1:00 pm

 

Clinical Diagnostics

Grifols growing portfolio of specialized clinical diagnostics is designed to detect and monitor treatment of infectious, autoimmune, and neurodegenerative diseases. Our comprehensive autoimmune portfolio of hardware, software, and reagents allow laboratories to simplify routine autoimmune testing, streamline workflow, and reduce hands-on time in the laboratory.

HELIOS – All-in-One IFA Processing and Reading

The HELIOS System is an FDA cleared instrument to provide all-in-one IFA HEp-2 slide processing and reading on one platform. The HELIOS combines reliable hardware, intuitive software, and quality reagents to transform the autoimmune testing workspace.

The HELIOS is FDA cleared for the following assays:

  • HEp-2 (7 patterns)
  • ANCA Ethanol and Formalin (2 patterns)
  • Crithidia luciliae – nDNA (1 pattern)

 

SQII – True Open Automation

SQII is a compact, flexible, open system ideal for running any ELISA test from autoimmune and infectious disease, to therapeutic drug monitoring. SQII was designed for high efficiency and reliability. The system has only a few moving parts which makes it simple to maintain and easy to use. SQII is adapted to run AESKULISA assays and can simultaneously process two 96-well microplates and up to four different assays using the AESKULISA racks and reagents, or twelve assays using standard racks.

The AESKULISA menu encompasses 155 autoimmune tests including 30 FDA cleared tests:

  • 13 FDA approved tests for Rheumatology
  • 6 FDA approved tests for Thrombosis
  • 9 FDA approved tests for Gastroenterology
  • 2 FDA approved tests for Vasculitis

 

 

               HELIOS – All-in-One IFA Processing
          and Reading

 

                SQII – True Open Automation

 

Typing

Grifols blood typing products cover the main demands of immunohematology laboratories, offering optimized technology for various testing needs and the expert support of a specialized global partner so that patients receive safer transfusions, right on time.

Discover how the DG Gel system is continuously growing by offering increased adaptability and making daily work easier. With scalable systems that adapt to laboratories' different throughput and capacities while using the same reagents and equivalent software, users can select the solution that is best suited for their typing needs.

  • Designed to adapt to different workflow needs
  • Developed to provide intuitive operation in a compact footprint

 

The Erytra Eflexis1: Adaptability that fits your lab

Introducing the Erytra Eflexis – the natural evolution in Grifols scalable blood typing solutions. This truly flexible system allows laboratories to select the solution that is best suited to different workflow needs and capacities.

The Erytra and Erytra Eflexis are true scalable systems that offer different throughput and capacities while using the same reagents and sharing the equivalent software suite. Therefore, you can select the solution that is best suited for your laboratory.

  • Smart
  • Flexible
  • Intuitive

 

Erytra system

 

Erytra Eflexis system

 

Wadiana system

 

DG Reader

 

 

ID CORE XT2

The ID CORE XT kit, part of the BLOODchip platform, provides extended blood group genotyping to support improved patient care. Match blood unit to patient with greater resolution for 10 blood group systems, down to the genotype.

ID CORE XT kit

  • Improve transfusion safety
  • Reduce time between transfusions for chronically transfused patients
  • Reduce your institution's bed stay times
  • Improve outcomes for your hematology, oncology, obstetric and pediatric patients
  • Reduce your blood bank laboratory's pretransfusion testing workload

 

Grifols Immunohematology Center & Clinical Laboratory

Grifols Immunohematology Center

Make your laboratory more productive to deliver optimal patient care. Our CLIA reference laboratory at the Grifols Immunohematology Center provides testing and support for some the most challenging cases, saving you time and resources that would otherwise be consumed by complex workups.

The Grifols Immunohematology Center gives you the tools to:

  • Take better precautions to decrease the risk of alloimmunization and transfusion reactions based on current scientific knowledge
  • Take better precautions to decrease the risk of HDFN (hemolytic disease of the fetus and newborn, based on current scientific knowledge) and unnecessary Rh immune globulin administration
  • Strengthen your own expertise 

 

Grifols Clinical Laboratory

Our lab offers specialized testing panels for selected medical needs like therapeutic drug monitoring and diagnosis of different genetic diseases like familial hypercholesterolemia (FH).

TDMonitor is a new panel of assays to measure levels of Infliximab (Remicade, Inflectra, Remsima), Adalimumab (Humira) or Vedolizumab (Entyvio) and the anti-drug antibodies. Test results support clinicians, hospitals, and laboratories globally in making therapeutic decisions, improving patient therapy strategy, and reducing the risk of debilitating disease progression. TDMonitor assays were developed and validated by Grifols CLIA-certified Clinical Laboratory in San Marcos, Texas. Samples may be mailed to the Texas laboratory. Following testing of the sample, a complete report which includes recommendations with references is generated and then submitted to the health care provider in 5-7 days.

Grifols offers genetic tests to diagnose familial hypercholesterolemia (FH) by using advanced sequencing technologies. FH is a condition present in 1 in 250 people worldwide. This genetic condition causes lifelong levels of high cholesterol, which can lead to early coronary artery disease.

1 The Erytra Eflexis analyzer is CE marked in accordance with the Directive EC of the European Parliament and of the Council of October on in vitro diagnostic medical devices. This product is FDA approved in the United States. Product registration and availability vary by country. To determine whether the Erytra Eflexis system is available for sale in your country, please contact your local Grifols representative.
2 ID CORE XT is CE marked and is FDA approved in the US. To determine whether ID CORE XT is available for sale in your country, please contact your local Grifols representative.

This information is intended for physicians and healthcare professionals only.

Product registration and availability vary by country. For more information on product availability, please contact us here.